Anticholinergics in Palliative Medicine: An Update

American Journal of Hospice and Palliative Medicine

Volumn 30, Issue 5, 2013, Pages 490-498

  Prommer, Eric ^a  

^a MAYO CLINIC HOSPITAL   (United States)

Author keywords

binding affinities; death rattle; malignant bowel obstruction; muscarinic; receptors; secretions

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

BINDING AFFINITIES; BODILY SECRETIONS; DEATH RATTLE; DRUG CONTRAINDICATION; HUMAN; MALIGNANT BOWEL OBSTRUCTION; METHODOLOGY; MUSCARINIC; PALLIATIVE THERAPY; RECEPTORS; REVIEW; TERMINAL CARE;

BINDING AFFINITIES; DEATH RATTLE; MALIGNANT BOWEL OBSTRUCTION; MUSCARINIC; RECEPTORS; SECRETIONS;

CHOLINERGIC ANTAGONISTS; HUMANS; PALLIATIVE CARE; TERMINAL CARE;

EID: 84881110935     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909112459366     Document Type: Review

References (56)

1. Billings JA.What is palliative care?.J Palliat Med. 1998;1 (1): 73-81.
2. Shah N,Khurana S,Cheng K,Raufman JP.Muscarinic receptors and ligands in cancer.Am J Physiol Cell Physiol. 2009;296 (2): C221-C232.
3. Rompler H,Staubert C,Thor D,Schulz A,Hofreiter M,Schoneberg T.G protein-coupled time travel: evolutionary aspects of GPCR research.Mol Interv. 2007;7 (1): 17-25.
4. Bymaster FP,McKinzie DL,Felder CC,Wess J.Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system.Neurochem Res. 2003;28 (3-4): 437-442.
5. Abrams P,Andersson KE,Buccafusco JJ, et al.Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.Br J Pharmacol. 2006;148 (5): 565-578.
6. Ikeda K,Kobayashi S,Suzuki M, et al.M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.Naunyn Schmiedebergs Arch Pharmacol. 2002;366 (2): 97-103.
7. Sutliff VE,Rattan S,Gardner JD,Jensen RT.Characterization of cholinergic receptors mediating pepsinogen secretion from chief cells.Am J Physiol. 1989;257 (2 pt 1): G226-G234.
8. Soll AH.Specific inhibition by prostaglandins E2 and I2 of histamine-stimulated [14C] aminopyrine accumulation and cyclic adenosine monophosphate generation by isolated canine parietal cells.J Clin Invest. 1980;65 (5): 1222-1229.
9. Zimmerman TW,Dobbins JW,Binder HJ.Mechanism of cholinergic regulation of electrolyte transport in rat colon in vitro.Am J Physiol. 1982;242 (2): G116-G123.
10. BrownJHLaikenN. Muscarinic Receptor Agonists and Antagonists. In: (2011). Chapter 9. In BruntonLLChabnerBAKnollmannBC eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed.2011. http://www.accessmedicine.com/content.aspx?aID@=16660596. Accessed September 3, 2012.
11. Ali-Melkkilä T,Kanto J,Iisalo E.Pharmacokinetics and related pharmacodynamics of anticholinergic drugs.Acta Anaesthesiol Scand. 1993;37 (7): 633-642.
12. MerelloMFarberNMRonES. methods and compositions for decreasing saliva production. Google patents. January 19, 2006.
13. Davis MP,Nouneh C.Modern management of cancer-related intestinal obstruction.Curr Oncol Rep. 2000;2 (4): 343-350.
14. Haddad EB,Patel H,Keeling JE,Yacoub MH,Barnes PJ,Belvisi MG.Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways.Br J Pharmacol. 1999;127 (2): 413-420.
15. Nachum Z,Shahal B,Shupak A, et al.Scopolamine bioavailability in combined oral and transdermal delivery.J Pharmacol Exp Ther. 2001;296 (1): 121-123.
16. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc; 2010:.
17. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc; 2010:.
18. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc; 2010:.
19. Putcha L,Cintrón NM,Tsui J,Vanderploeg JM,Kramer WG.Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.Pharm Res. 1989;6 (6): 481-485.
20. Renner UD,Oertel R,Kirch W.Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.Ther Drug Monit. 2005;27 (5): 655-665.
21. Ebert U,Siepmann M,Oertel R,Wesnes KA,Kirch W.Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.J Clin Pharmacol. 1998;38 (8): 720-726.
22. Ebert U,Oertel R,Kirch W.Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects.Int J Clin Pharmacol Ther. 2000;38 (11): 523-531.
23. Ebert U,Grossmann M,Oertel R,Gramatte T,Kirch W.Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers.J Clin Pharmacol. 2001;41 (1): 51-60.
24. Parrott AC.Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.Aviat Space Environ Med. 1989;60 (1): 1-9.
25. Ali-Melkkil S T,Kaila T,Kanto J.Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings.Acta Anaesthesiol Scand. 1989;33 (6): 513-517.
26. Dickman A,Schneider J,Varga JThe Syringe Driver: Continuous Subcutaneous Infusions in Palliative Care. USA: Oxford University Press; 2005:.
27. Ali-Melkkila TM,Kaila T,Kanto J,Iisalo E.Pharmacokinetics of im glycopyrronium.Br J Anaesth. 1990;64 (6): 667-669.
28. Kaltiala E,Penttil SA,Vapaatalo H,Larmi T.The fate of intravenous (3H) glycopyrrolate in man.J Pharm Pharmacol. 1974;26 (5): 352-354.
29. Beermann B,Hellström K,Rosen A.The gastrointestinal absorption of atropine in man.Clin Sci. 1971;40 (1): 95-106.
30. Kentala E,Kaila T,Iisalo E,Kanto J.Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study.Int J Clin Pharmacol Ther Toxicol. 1990;28 (9): 399-404.
31. Ebert U,Siepmann M,Oertel R,Wesnes KA,Kirch W.Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.J Clin Pharmacol. 1998;38 (8): 720-726.
32. Berghem L,Berghem U,Schildt B,Sorbo B.Plasma atropine concentrations determined by radioimmunoassay after single-dose iv and im administration.Br J Anaesth. 1980;52 (6): 597-601.
33. Adams RG,Verma P,Jackson AJ,Miller RL.Plasma pharmacokinetics of intravenously administered atropine in normal human subjects.J Clin Pharmacol. 1982;22 (10): 477-481.
34. Kanto J.Oropharyngeal absorption of atropine.Int J Clin Pharmacol Ther Toxicol. 1986;24 (11): 627-629.
35. Bray BM,Jones HM,Grundy EM.Tracheal versus intravenous atropine.Anaesthesia. 1987;42 (11): 1188-1190.
36. Harrison LI,Smallridge RC,Lasseter KC, et al.Comparative absorption of inhaled and intramuscularly administered atropine.Am Rev Respir Dis. 1986;134 (2): 254-257.
37. Tytgat GN.Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain.Drugs. 2007;67 (9): 1343-1357.
38. Herxheimer A,De Groot AC.Some effects of injected hyoscine butylbromide: a versatile class experiment in human pharmacology.Br J Clin Pharmacol. 1977;4 (3): 337-342.
39. Kentala E,Kaila T,Ali-Melkkil S T,Kanto J.beta-Glucuronide and sulfate conjugation of scopolamine and glycopyrrolate.Int J Clin Pharmacol Ther Toxicol. 1990;28 (11): 487-489.
40. Kalser SC,McLain PL.Atropine metabolism in man.Clin Pharmacol Ther. 1970;11 (2): 214-227.
41. Kirvela M,Ali-Melkkila T,Kaila T,Iisalo E,Lindgren L.Pharmacokinetics of glycopyrronium in uraemic patients.Br J Anaesth. 1993;71 (3): 437-439.
42. Hinderling PH,Gundert-Remy U,Schmidliny O,Heinzel G.Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans II: pharmacodynamics.J Pharm Sci. 1985;74 (7): 711-717.
43. Olsen AK,Sjøgren P.Oral glycopyrrolate alleviates drooling in a patient with tongue cancer.J Pain Symptom Manage. 1999;18 (4): 300-302.
44. Seymour RM,Routledge PA.Important drug-drug interactions in the elderly.Drugs Aging. 1998;12 (6): 485-494.
45. Likar R,Rupacher E,Kager H,Molnar M,Pipam W,Sittl R.Die Wirkung von Glycopyrroniumbromid im Vergleich mit Scopolamin-Hydrobromicum beim terminalen Rasseln: Eine randomisierte, doppelblinde Pilotstudie.Wien Klin Wochenschr. 2008;120 (21-22): 679-683.
46. Back IN,Jenkins K,Blower A,Beckhelling J.A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle.Palliat Med. 2001;15 (4): 329-336.
47. Hughes A,Wilcock A,Corcoran R,Lucas V,King A.Audit of three antimuscarinic drugs for managing retained secretions.Palliat Med. 2000;14 (3): 221-222.
48. Hugel H,Ellershaw J,Gambles M.Respiratory tract secretions in the dying patient: a comparison between glycopyrronium and hyoscine hydrobromide.J Palliat Med. 2006;9 (2): 279-284.
49. Wildiers H,Dhaenekint C,Demeulenaere P, et al.Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care.J Pain Symptom Manage. 2009;38 (1): 124-133.
50. Clark K,Currow DC,Agar M,Fazekas BS,Abernethy AP.A pilot phase II randomized, cross-over, double-blinded, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end-of-life.J Pain Palliat Care Pharmacother. 2008;22 (2): 131-138.
51. De Simone GG,Eisenchlas JH,Junin M,Pereyra F,Brizuela R.Atropine drops for drooling: a randomized controlled trial.Palliat Med. 2006;20 (7): 665-671.
52. Mystakidou K,Tsilika E,Kalaidopoulou O,Chondros K,Georgaki S,Papadimitriou L.Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial.Anticancer Res. 2002;22 (2B): 1187-1192.
53. Mercadante S,Ripamonti C,Casuccio A,Zecca E,Groff L.Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.Support Care Cancer. 2000;8 (3): 188-191.
54. Bachrach SJ,Walter RS,Trzcinski K.Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy.Clin Pediatr (Phila). 1998;37 (8): 485-490.
55. Rougier P,Bugat R,Douillard JY, et al.Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.J Clin Oncol. 1997;15 (1): 251-260.
56. Bauwesein C,Twycross RG.Comparative cost of hyoscine injections.Palliat Med. 1995;9 (3): 256.